Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 8—August 2009
Research

Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

Iain StephensonComments to Author , Alan Heath, Diane Major, Robert W. Newman, Katja Hoschler, Wang Junzi, Jacqueline M. Katz, Jerry P. Weir, Maria C. Zambon, and John M. Wood
Author affiliations: University of Leicester, Leicester, UK (I. Stephenson); National Institute for Biological Standards and Controls, Potters Bar, UK (A. Heath, D. Major, R.W. Newman, J.M. Wood); Health Protection Agency, Colindale, UK (K. Hoschler, M.C. Zambon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Katz); Food and Drug Administration, Rockville, Maryland, USA (J.P. Weir); National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China (W. Junzhi)

Main Article

Table 2

Geometric mean titers and percentage coefficient of variations of absolute titers and titers relative to candidate antibody standard 07/150 for each serum sample for each influenza virus by hHI and neutralization*†

Serum sample Virus assay, antigen, and clade
hHI (GMT, %GCV, %GCV relative to 07/150)
 Neutralization (GMT, %GCV, %GCV relative to 07/150)
NIBRG-14 
clade 1 NIBRG-23 
clade 2.2 IBCDC-RG5 clade 2.3 NIBRG-14 
clade 1 NIBRG-23 clade 2.2 IBCDC-RG5 clade 2.3
Prevaccination
B 7, 110, 72 7, 111, 86 6, 112, 85 12, 176, 202 12, 141, 173 10, 68, 223
N 6, 31, 46 5, 29, 18 5, 22, 0 14, 175, 228 13, 160, 215 10, 186, 250
J
 10, 111, 123
 8, 81, 155
 6, 43, 96
19, 175, 228
 18, 218, 309
 11, 102, 287
Postvaccination
Low
C 34, 84, 36 17, 29, 18 10, 126, 164 63, 183, 80 27, 201, 236 23, 122, 206
D 15, 141, 105 8, 110, 127 6, 68, 45 19, 232, 248 15, 215, 288 12, 98, 226
High
E 104, 133, 58 60, 96, 36 8, 128, 141 148, 191, 81 87, 159, 42 20, 118, 223
F 78, 97, 55 16, 141, 116 20, 104, 105 83, 144, 62 18, 152, 234 35, 147, 196
G 281, 152, 61 147, 102, 131 44, 163, 144 504, 132, 37 274, 217, 83 140, 103, 45
H 95, 118, 66 42, 144, 116 18, 106, 111 130, 166, 74 91, 157, 33 34, 127, 154
I 351, 125, 60 93, 91, 47 107, 75, 44 379, 199, 71 106, 207, 191 161, 136, 41
A 391, 138, 55 335, 114, 34 448, 119, 51 1,389, 86, 45 1,313,125, 76 2,893, 78, 63
L
 391, 147, 61
 398, 145, 42
 480, 108, 44
1,453, 104, 63
 1,520, 101, 85
 3,097, 73, 52
False positive (K)
 37, 120, 34
 24, 136, 135
 8, 81, 117
52, 185, 143
 44, 185, 53
 13, 112, 298
Sheep
O 48, 262, 285 30, 245, 338 17, 147, 319 216, 139, 53 148, 170, 33 49, 117, 156
P 1,857, 582, 535 1,171, 496, 487 1,338, 487, 545 7,317, 148, 196 732, 283, 144 3,806, 145, 59

*GMT geometric mean titer; %GCV, percentage geometric coefficient of variation; hHI, hemagglutination-inhibition assay using horse erythrocytes; neutralization, virus neutralization assay. (Paired samples were B and C, N and F, and J and H.)
†Overall serum samples, GMT by neutralization vs. hHI (p = 0.001, NIBRG-14; p = 0.008, NIBRG-23; p = 0.001, IBCDC-RG5; Wilcoxon signed-rank test).

Main Article

Page created: November 01, 2010
Page updated: November 01, 2010
Page reviewed: November 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external